Abstract
Hydroxychloroquine (HCQ)-induced neutropenia is very rare in children. Even though idiosyncratic HCQ-induced neutropenia is mentioned as a possible side effect reported in the adult population, no pediatric cases have been published in the literature. We present an infant with severe neutropenia after HCQ therapy during the early COVID-19 pandemic. A 2-month-old infant with severe neutropenia after HCQ therapy during the early COVID-19 pandemic. After the neutrophil count returned to normal within a week of stopping the HCQ, and all other possible causes were ruled out, the diagnosis of HCQ-induced neutropenia was made. This case appears to be the first reported pediatric patient with severe neutropenia following the administration of HCQ. HCQ should be used with caution in young infants and only when strongly indicated. Idiosyncratic drug-induced neutropenia is typically serious in infants and mandates prompt diagnosis and management. When patients begin treatment with a drug that can cause neutropenia, neutrophil counts must be carefully monitored, especially in the first 2 days. Furthermore, if neutropenia occurs, we recommend neutrophil monitoring until complete recovery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
